
Medifast Inc (NYSE:MED – Free Report) – Equities research analysts at Zacks Research boosted their FY2026 EPS estimates for shares of Medifast in a research report issued to clients and investors on Monday, November 16th. Zacks Research analyst Team now expects that the specialty retailer will post earnings of ($0.52) per share for the year, up from their prior estimate of ($1.04). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Medifast’s current full-year earnings is ($0.57) per share. Zacks Research also issued estimates for Medifast’s Q4 2026 earnings at $0.14 EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.56) EPS, Q1 2028 earnings at ($0.15) EPS, Q3 2028 earnings at ($0.33) EPS and FY2028 earnings at ($0.49) EPS.
Medifast (NYSE:MED – Get Free Report) last issued its earnings results on Monday, October 26th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.16. Medifast had a negative net margin of 13.64% and a negative return on equity of 6.90%. The business had revenue of $72.05 million for the quarter, compared to analysts’ expectations of $71.30 million.
Separately, Weiss Ratings cut Medifast from a “sell (d)” rating to a “sell (d-)” rating in a research report on Wednesday, October 28th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $12.00.
Get Our Latest Analysis on Medifast
Medifast Price Performance
NYSE:MED opened at $12.22 on Wednesday. The company has a market cap of $136.66 million, a P/E ratio of -3.31 and a beta of 0.65. The stock’s fifty day moving average price is $12.15 and its two-hundred day moving average price is $11.40. Medifast has a 1 year low of $9.22 and a 1 year high of $13.63.
Hedge Funds Weigh In On Medifast
Hedge funds have recently bought and sold shares of the company. Ancora Advisors LLC increased its holdings in Medifast by 411.5% during the 3rd quarter. Ancora Advisors LLC now owns 36,110 shares of the specialty retailer’s stock worth $416,000 after acquiring an additional 29,050 shares during the period. Marshall Wace LLP boosted its holdings in Medifast by 46.0% in the 3rd quarter. Marshall Wace LLP now owns 352,704 shares of the specialty retailer’s stock valued at $4,063,000 after purchasing an additional 111,055 shares during the period. Advisors Asset Management Inc. bought a new position in Medifast in the 3rd quarter valued at $106,000. Commons Capital LLC boosted its holdings in Medifast by 23.0% in the 3rd quarter. Commons Capital LLC now owns 184,432 shares of the specialty retailer’s stock valued at $2,125,000 after purchasing an additional 34,516 shares during the period. Finally, Engineers Gate Manager LP grew its position in shares of Medifast by 25.9% during the 2nd quarter. Engineers Gate Manager LP now owns 49,829 shares of the specialty retailer’s stock valued at $529,000 after purchasing an additional 10,249 shares in the last quarter. Hedge funds and other institutional investors own 95.51% of the company’s stock.
Insider Transactions at Medifast
In other Medifast news, Director Daniel Chard sold 9,545 shares of Medifast stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $11.98, for a total transaction of $114,349.10. Following the completion of the transaction, the director owned 140,153 shares of the company’s stock, valued at $1,679,032.94. The trade was a 6.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Parsa Kiai purchased 43,150 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were bought at an average price of $12.26 per share, for a total transaction of $529,019.00. Following the completion of the transaction, the director owned 707,492 shares of the company’s stock, valued at approximately $8,673,851.92. This trade represents a 6.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 96,847 shares of company stock valued at $1,158,138 in the last ninety days. Insiders own 3.70% of the company’s stock.
Top Medifast Stories
Here are a few of the latest stories about MED:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to a loss of $0.52 from a loss of $1.04, and its Q4 2026 estimate to earnings of $0.14 from a loss of $0.17. It also modestly improved its Q1 2028 estimate to a loss of $0.15 from $0.16.
- Neutral Sentiment: Zacks maintained a “Hold” rating on Medifast.
- Negative Sentiment: Most revisions were cuts: estimates for FY2027 and FY2028 were lowered to losses of $0.56 and $0.49 per share, respectively. Forecasts for multiple quarters in 2027 and Q3 2028 were also reduced, including Q3 2028 to a loss of $0.33 from $0.09. The broader pattern of weaker projected earnings could weigh on investor sentiment.
Medifast Company Profile
Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company’s approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company’s programs.
See Also
- Five stocks we like better than Medifast
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.
